Pharma Industry

Swati Piramal: Ajay Piramal eyes next leg of growth, but the model of growing through buyouts has stiff competition

Piramal Healthcare UK Ltd at Morpeth; image credit: Piramal Group


His broad plays — a global business of contract manufacturing; making critical-care medicines used in hospitals; and selling OTC drugs in India— all have the potential for significant scale, but they come with their share of challenges. Also, a re-entry in the domestic pharma formulations business won’t be as easy as popping a pill.

Like an astute investor, he knows just when to enter the market and exit it. Back in 2010, Ajay Piramal made a pile with an exit that made the Indian pharma market release a collective gasp. Not that he ever left his happy hunting ground of pharma, but he is now dropping hints that he is looking to grab some juicy morsels in the sector once again.There is one thing every investment banker agrees with: Big deals and business tycoon Ajay Piramal

  • SAVE

Sign in to read the full article

You’ve got this Prime Story as a Free Gift

Already a Member?

Why ?

  • Sharp Insight-rich, Indepth stories across 20+ sectors

  • Access the exclusive Economic Times stories, Editorial and Expert opinion

  • Clean experience with
    Minimal Ads

  • Comment & Engage with ET Prime community

  • Exclusive invites to Virtual Events with Industry Leaders

  • A trusted team of Journalists & Analysts who can best filter signal from noise

Source link